18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features

Zhou, Xiang; Dierks, Alexander; Kertels, Olivia; Kircher, Malte; Schirbel, Andreas; Samnick, Samuel; Buck, Andreas K.; Knorz, Sebastian; Böckle, David; Scheller, Lukas; Messerschmidt, Janin; Barakat, Mohammad; Kortüm, K. Martin; Rasche, Leo; Einsele, Hermann; Lapa, Constantin

doi:10.3390/cancers12082333

Cited by 21 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positron-emission tomography/computed tomography (PET/ CT) with fluorine-18 fluorodeoxyglucose ( 18 F-FDG) has been applied for the assessment of systemic tumor burden, response evaluation, and survival prediction in MM (5)(6)(7)(8)(9), for it provides 'functional' information regarding lesions as well as metabolic and anatomic information. Compared with traditional X-rays, systemic CT is a sensitive technique to detect the presence of bone lesions and/or BM involvement at the onset of MM (7).…”

Section: Introductionmentioning

confidence: 99%

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

To assess patients with multiple myeloma (MM), the whole-body positron-emission tomography/computed tomography (PET/CT) occupies a pivotal position for diagnostic stratification, response evaluation, and survival prediction, while important limitations are recognized as incapable of representing tumor microenvironment. Regulatory B cells (Bregs) have been reported to have an inhibitory immune function, contributing to bone marrow (BM)-immunosuppressive microenvironment for MM. Therefore, to investigate the role of PET/CT in combination with Bregs’ ratios to predict therapeutic response and survival, we sequentially enrolled 120 patients with newly diagnosed MM (NDMM) who were treated with novel agents in our center, while conventional PET/CT parameters including maximum standard uptake value (SUVmax), ratios of BM-derived Bregs within CD19+ B cells, and patients’ clinical characteristics were collected. After a median follow-up of 28.20 months (range 7.00–46.93 months), SUVmax > 4.2 at onset, accounting for 53.2% of NDMM, was uncovered to predict inferior progression-free survival (PFS) as well as overall survival (OS). With regard to the ratios of BM-derived Bregs within CD19+ B cells, the cohort with the Bregs’ proportions lower than 10%, accounting for 46.2%, exerted poorer OS. Additionally, the patients with both SUVmax > 4.2 and Bregs’ ratios < 10%, accounting for 31.7%, yielded compromised therapeutic response and long-term survival. Collectively, this study may draw attention on the prognostic value of combination of PET/CT and Bregs’ ratios when clinical decisions are made for MM in the era of novel agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A significant correlation was confirmed between BM plasma cell (BMPC) infiltration and the mean target-to-background ratio (TBR mean ) on 11 C-MET in the lumbar vertebrae of SMM patients (r = 0.789), which is close to that for 68 Ga-Pentixafor (r = 0.724), but higher than that for 18 F-FDG PET/CT (r = 0.355) (31).…”

Section: Clinical Value Of 11 C-met-pet In MMmentioning

confidence: 59%

“…Quantitative analysis has been performed using the maximum standardized uptake (SUV max ) and mean standardized uptake (SUV mean ) values of the identified MM lesions, in which the SUV max of 11 C-MET tended to be higher than that of 18 F-FDG. 11 C-MET was found to detect more focal MM lesions than 18 F-FDG (8,27,30), and a higher 11 C-MET uptake was related to poor prognosis (31).…”

Section: Clinical Value Of 11 C-met-pet In MMmentioning

confidence: 90%

“…Several studies have demonstrated that 68 Ga-Pentixafor was superior or equal to 18 F-FDG PET/CT in the diagnosis of MM (34,35). By comparing 68 Ga-Pentixafor and 11 C-MET PET with 18 F-FDG PET/CT, the greater sensitivity of 68 Ga-Pentixafor and 11 C-MET PET/CT in the evaluation of BM involvement in patients with SMM was demonstrated (31).…”

Section: Clinical Value Of 11 C-met-pet In MMmentioning

confidence: 99%

See 1 more Smart Citation

Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma

Minamimoto

2022

Front. Nucl. Med.

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy characterized by infiltration of monoclonal plasma cells in the bone marrow (BM). The standard examination performed for the assessment of bone lesions has progressed from radiographic skeletal survey to the more advanced imaging modalities of computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT). The Durie–Salmon PLUS staging system (upgraded from the Durie–Salmon staging system) applies 2-[18F]-fluoro-2-deoxy-glucose (18F-FDG) PET/CT, and MRI findings to the staging of MM, and 18F-FDG PET/CT has been incorporated into the International Myeloma Working Group (IMWG) guidelines for the diagnosis and staging of MM. However, 18F-FDG PET/CT has significant limitations in the assessment of diffuse BM infiltration and in the differentiation of MM lesions from inflammatory or infectious lesions. The potential of several new PET tracers that exploit the underlying disease mechanism of MM has been evaluated in terms of improving the diagnosis. L-type amino acid transporter 1 (LAT1), a membrane protein that transports neutral amino acids, is associated with cell proliferation and has strong ability to represent the status of MM. This review evaluates the potential of amino acid and proliferation PET tracers for diagnosis and compares the characteristics and accuracy of non-FDG tracers in the management of patients with MM.

show abstract

“…Recently, Zhou et al. ( 30 ) evaluated for the first time the role of 11C-Met PET/CT and 68Ga-Pentixafor PET/CT in 10 smoldering multiple myeloma patients, compared to 18F-FDG PET/CT.…”

Section: New Tracersmentioning

confidence: 99%

PET/CT in Multiple Myeloma: Beyond FDG

et al. 2021

View full text Add to dashboard Cite

Recent advances in the diagnosis and treatment of multiple myeloma (MM) have highlighted the importance of imaging methods, not only in the localization and extent of the disease but also in prognostic stratification and assessment of response to therapy. In this context, PET/CT, combining both morphological and functional information, is particularly useful in this pathology. The tracer mostly used is 18F-FDG, a glucose analog, which provides extremely accurate information with a sensitivity ranging from 80 to 100%. However, this tracer has some limitations, mostly related to the physiological uptake of FDG in the bone marrow and brain, which reduce its effectiveness. For this reason, some studies in the literature have evaluated the effectiveness of other PET tracers, which provide information on protein metabolism or the synthesis of metabolic plasma membranes, such as choline and methionine, as well as innovative radiopharmaceuticals, directed against receptors expressed by cells of myeloma, including tracers directed to the chemokine receptor. This review analyzes the characteristics and accuracy of non-FDG tracers in the management of patients with multiple myeloma.

show abstract

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features

Cited by 21 publications

References 20 publications

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma

PET/CT in Multiple Myeloma: Beyond FDG

Contact Info

Product

Resources

About